EcoDrugPlus

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSHBUG00000023398
Gene Symbol: UGCG
3 Cross references
211 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSHBUG00000016789
Gene Symbol: WEE1
3 Cross references
205 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSHBUG00000016658
Gene Symbol: YES1
4 Cross references
208 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSHBUG00000007747
Gene Symbol: ACVR2B
3 Cross references
195 Possible Orthologues:

Activin Receptor Type-2b-Like

Ensembl ID : ENSHBUG00000007527
Gene Symbol: LOC102288687
3 Cross references
193 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSHBUG00000001334
Gene Symbol: ADORA1
3 Cross references
204 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSHBUG00000001594
Gene Symbol: ADORA2A
3 Cross references
189 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSHBUG00000001331
Gene Symbol: ADORA2A
3 Cross references
198 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSHBUG00000021435
Gene Symbol: ADORA2B
3 Cross references
199 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSHBUG00000008168
Gene Symbol: ADA
3 Cross references
216 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSHBUG00000022466
Gene Symbol: LOC102295923
3 Cross references
173 Possible Orthologues:

Adenosine Receptor A3-Like

Ensembl ID : ENSHBUG00000006534
Gene Symbol: LOC102293999
2 Cross references
39 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).